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Summary
Five TLRs are thought to play an important role in an-
tiviral immunity, sensing viral products and inducing
IFN-a/b and -l. Surprisingly, patients with a defect of
IRAK-4, a critical kinase downstream from TLRs, are
resistant to common viruses. We show here that IFN-
a/b and -l induction via TLR-7, TLR-8, and TLR-9 was
abolished in IRAK-4-deficient blood cells. In contrast,
IFN-a/b and -l were induced normally by TLR-3 and
TLR-4 agonists. Moreover, IFN-b and -l were normally
induced by TLR-3 agonists and viruses in IRAK-4-
deficient fibroblasts. We further show that IFN-a/b
and -l production in response to 9 of 11 viruses tested
was normal or weakly affected in IRAK-4-deficient
blood cells. Thus, IRAK-4-deficient patients may con-
trol viral infections by TLR-3- and TLR-4-dependent
and/or TLR-independent production of IFNs. The
TLR-7-, TLR-8-, and TLR-9-dependent induction of IFN-
a/b and -l is strictly IRAK-4 dependent and para-
doxically redundant for protective immunity to most
viruses in humans.
Introduction
IL-1R-associated kinase (IRAK)-4 deficiency is the first
reported inherited defect in the common Toll/IL-1 recep-
tor (TIR) signaling pathway in humans (Ku et al., 2005;
Picard et al., 2003). Since the original description of
three patients (Picard et al., 2003), IRAK-4 deficiency
has been identified in 18 individuals with a consistent
cellular phenotype (Cardenes et al., 2005; Chapel et al.,
2005; Currie et al., 2004; Day et al., 2004; Enders et al.,
2004; Medvedev et al., 2003; Picard et al., 2003; this re-
port). IRAK-4-deficient blood cells have been shown not
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466to produce the following proinflammatory cytokines: in-
terleukin-1b (IL-1b), IL-6, IL-12, tumor necrosis factor-a
(TNF-a), and interferon-g (IFN-g), in response to IL-1b,
IL-18, and all Toll-like receptor (TLR) agonists tested,
including PAM3CSK4 (an agonist of TLR-1 and -2),
PAM2CSK4 and Zymosan (TLR-2 and -6), Staphylococ-
cus aureus lipoteichoic acid (LTA) (TLR-2), poly(I:C)
(TLR-3), lipopolysaccharide (LPS) (TLR-4), flagellin
(TLR-5), and unmethylated CpG DNA (TLR-9). Recently
described TLR-7 and -8 agonists, such as imidazoquin-
oline compounds (imiquimod and R-848), and GU-rich
single-stranded (ss) RNAs have not been tested in
IRAK-4-deficient patients. Fibroblasts are the only cells
from these patients other than unselected blood cells to
have been tested; they do not produce IL-6 in response
to IL-1b (Picard et al., 2003).
The 18 individuals with IRAK-4 deficiency originate
from 11 unrelated families from Hungary (C.L. Ku et al.,
submitted), Portugal (Picard et al., 2003), Spain (Car-
denes et al., 2005), the United Kingdom (Chapel et al.,
2005), Israel (J.-L.C. and B.-Z.G., this report), Saudi Ara-
bia (Picard et al., 2003), Turkey (Enders et al., 2004), Can-
ada (Currie et al., 2004; C.R. and D.S., this report), and
the United States (Day et al., 2004; Medvedev et al.,
2003; Picard et al., 2003). IRAK-4-deficient patients suf-
fer from pyogenic bacterial infections. Gram-positive
bacteria are the most common pathogens identified in
these patients, with Streptococcus pneumoniae found
in most patients and Staphylococcus aureus in approx-
imately half the patients. In contrast, only three invasive
infections caused by gram-negative bacteria have been
reported (Cardenes et al., 2005; Chapel et al., 2005;
Medvedev et al., 2003). Interestingly, the clinical fea-
tures associated with this condition seem to improve
with age, as eight of the patients died in early childhood
but the four oldest patients, now aged 22, 25 (monozy-
gous twins), and 31, are well with no treatment (Chapel
et al., 2005; Medvedev et al., 2003; C.R., this report).
The most surprising observation remains that IRAK-4-
deficient patients present such a narrow range of sus-
ceptibility to infection, with apparently normal resis-
tance to the various infections commonly encountered
in childhood, including viral illnesses in particular.
Five TLRs (TLR-3, -4, -7, -8, -9) have been shown to in-
duce IFN-a/b and IFN-l production (Akira and Takeda,
2004; Coccia et al., 2004; Katze et al., 2002; Pestka
et al., 2004). Four (TLR-3, -7, -8, -9) are intracellular
TLRs stimulated by nucleic acids that may be produced
in the course of viral infections, leading to IFN-a/b and -l
production. TLR-3 can be stimulated by double-
stranded RNA (Alexopoulou et al., 2001); TLR-7 and -8
(in humans only) by antiviral derivatives of nucleoside-
like imidazoquinoline (Hemmi et al., 2002; Jurk et al.,
2002) and loxoribine (Heil et al., 2003) and GU-rich
ssRNAs (Diebold et al., 2004; Heil et al., 2004; Lund
et al., 2004); and TLR-9 by unmethylated double-
stranded (ds) CpG-rich DNA (Bauer et al., 2001; Hemmi
et al., 2000). Cell-surface TLR-4 induces IFN-a/b and -l
after stimulation with LPS (Coccia et al., 2004; Kato
et al., 2004; Toshchakov et al., 2002). However, TLR-3-
deficient mice are no more susceptible than wild-type
(wt) mice to vesicular stomatitis virus (VSV) and reovirus
(Edelmann et al., 2004), and TLR-4-deficient mice are no
more susceptible than wt mice to respiratory syncytialvirus (RSV) (Ehl et al., 2004) and the related Sendai virus
(van der Sluijs et al., 2003). TLR-3-deficient mice are
more susceptible to mouse cytomegalovirus (MCMV)
in some (Tabeta et al., 2004), but not all (Edelmann
et al., 2004), conditions. TLR-3-deficient mice are para-
doxically more resistant than wt mice to coxsackievirus
(Fairweather et al., 2003) and West Nile virus (Wang
et al., 2004). The susceptibility of TLR-9-deficient mice
to MCMV provides the best evidence that TLR-induced
IFNs are involved in antiviral immunity in vivo (Krug et al.,
2004; Tabeta et al., 2004).
The pathways leading to IFN-a/b production have be-
gun to be unraveled in recent years (Akira and Takeda,
2004; Coccia et al., 2004). TLRs activate a ‘‘canonical,’’
inflammatory signaling pathway via the TIR domain-
containing molecule MyD88 (which binds to all TLRs,
with the possible exception of TLR-3) and TIRAP (which
binds only TLR-2 and -4) and the IRAK complex, leading
to the activation of NF-kB and MAPK. ‘‘Alternative’’
pathways result in the production of IFN-a/b in response
to the stimulation of TLR-3, -4, -7, -8, and -9. TLR-3 and
TLR-4 can signal independently of MyD88, via TRIF
(Hoebe et al., 2003a; Yamamoto et al., 2003), which in-
duces IFN-b gene transcription, partly through IRF-3 ac-
tivation (Servant et al., 2002). IKK3, TBK1, and NAP1
have been shown to activate IRF-3 in response to
TLR-3 and -4 (Fitzgerald et al., 2003; Sasai et al., 2005;
Sharma et al., 2003). TLR-7, -8, and -9 seem to activate
some IFN-a genes directly, via the formation of a
MyD88-TRAF6-IRF-7 complex (Honda et al., 2004; Ka-
wai et al., 2004). In mice, IRAK-1 was shown to phos-
phorylate IRF-7 in this process (Uematsu et al., 2005).
In IRAK-4-deficient mouse cells, IFN-b is induced by
TLR-4 (Suzuki et al., 2003), but the responses to stimula-
tion of the intracellular receptors TLR-3, -7, -8, and -9
have not been examined. We investigated the produc-
tion of IFN-a/b and IFN-l in response to TLR and IL-1R
agonists in IRAK-4-deficient human patients to deter-
mine why these patients display normal resistance to vi-
ruses and to define the role of human IRAK-4 and TLRs
in IFN induction.
Results
IFN-a/b and -l Induction via TLRs in Control Blood
Cells
We stimulated PBMCs from healthy individuals (9 adults
and 2 children) with various TLRs agonists (see Supple-
mental Data available with this article online) and with
HSV-1 and VSV as controls of IFN-a/b and IFN-l induc-
tion. Viruses (Supplemental Data) and agonists of TLR-3
(poly(I:C)), TLR-7 (3M-13, R-848), TLR-8 (3M-2, R-848),
and TLR-9 (CpG-C274, selected from various CpG oligo-
nucleotides based on potent IFN-a/b-inducing capacity)
induced detectable levels of IFN-a (Figure 1A), IFN-b
(Figure 1B), and IFN-l1 (also known as IL-29, referred
to hereafter as IFN-l; data not shown) in the superna-
tant, as measured by ELISA after 24 hr of stimulation.
Similar results were obtained with the TLR-7 and -8 ag-
onists GU-rich ssRNA 33 and 40 (data not shown). We
did not determine experimentally whether poly(I:C),
which activates various pathways in human cells (Bala-
chandran et al., 2004; Kato et al., 2005; Maggi et al.,
2000), induced IFN-a/b via TLR-3 in our assay. No such
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467Figure 1. Production of IFN-a/b in Response
to TLR Agonists, HSV-1, and VSV in Blood
Cells from Healthy Controls and IRAK-4-Defi-
cient Patients
PBMCs from nine healthy adults and two
healthy children used as controls and from
IRAK-4-deficient patients P1, P2, and P3
were left unstimulated, stimulated with TLR
agonists, or infected with HSV-1 and VSV in
the following conditions: medium (Med),
poly(I:C) (50 mg/ml, an agonist of TLR-3),
LPS (100 ng/ml, TLR-4), flagellin (10 ng/ml,
TLR-5), 3M-13 (3 mg/ml, TLR-7), 3M-2 (3 mg/
ml, TLR-8), R-848 (5 mg/ml, TLR-7/8), CpG-
C274 (5 mg/ml, TLR-9), HSV-1 (MOI: 1), VSV
(MOI: 1). Experiments were carried out twice
for each patient.
(A and B) IFN-a secretion (A) and IFN-b secre-
tion (B) were measured by ELISA after 24 hr of
stimulation.
(C) IFN-b mRNA levels were analyzed by re-
verse transcription and real-time quantitative
PCR, 2 hr after stimulation for TLR-3, -4, -5,
-7, and -8, 6 hr after stimulation for TLR-9,
and 24 hr after infection for HSV-1 and VSV,
corresponding to the respective peaks of in-
duction. Means and standard deviations (SD)
were calculated for each patient from two ex-
periments, and for the controls from 11 inde-
pendent individuals, each tested once.
(D) PBMCs from a healthy control and from
IRAK-4-deficient patient P7 were left unstim-
ulated or stimulated with poly(I:C) (50 mg/ml),
IFN-b (8 3 104 U/ml), or both for 36 hr. IFN-
a was measured by ELISA. The experiment
shown is representative of two independent
experiments.induction was observed with agonists of TLR-1/2
(PAM3CSK4), TLR-2/6 (PAM2CSK4, Zymosan) (data not
shown), TLR-4 (LPS), and TLR-5 (flagellin) (Figures 1A
and 1B and data not shown). LPS, an agonist of TLR-4,
also induced IFN-b mRNA production, as shown by re-
verse transcription and Q-PCR (Figure 1C and data not
shown). IFN-a secretion peaked 24 to 48 hr after TLR
stimulation and viral stimulation (data not shown). IFN-b
mRNA induction in response to TLR-3, -4, -7, and -8peaked 2 hr after stimulation (data not shown). TLR-9-
induced and virus-induced IFN-b mRNA levels peaked
6 to 12 and 16 to 24 hr after stimulation, respectively
(data not shown). IFN-l secretion was measured 24 hr
after stimulation. The TLR-7, -8, and -9 agonists tested
strongly induced IFN-a/b and -l, to levels similar to
those for the two viruses tested. In contrast, agonists
of TLR-3 and TLR-4 were less potent (Supplemental
Data).
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468Figure 2. Flow Cytometry Analysis of Blood
Monocyte Subsets, Plasmacytoid, and Mye-
loid Dendritic Cells in IRAK-4 Deficient
Patients
Monocyte subsets, plasmacytoid dendritic
cells (PDCs), and myeloid dendritic cells
(MDCs) in PBMC from an IRAK-4-deficient
patient (P2), as determined by FACS.
(A) HLA-DR+, CD14+/162 (magenta), CD14low
CD16high (green), and CD14+/16+ (blue), mono-
cyte subsets.
(B) HLA-DR+, BDCA-2+, CD123+ plasmacy-
toid dendritic cells.
(C) HLA-DR+, lin2, BDCA-1+, CD11c+ myeloid
dendritic cells. All subsets were present at
the expected frequency.
(D) Percentage of monocytes, PDCs, and
MDCs, among PBMC, in IRAK-4-deficient pa-
tients P2 and P3 and healthy donors.IFN-a/b and IFN-l Induction via TLRs in IRAK-4-
Deficient Blood Cells
PBMCs from three IRAK-4-deficient patients (P1, P2, P3)
(Supplemental Data) did not respond to TLR-7, -8, and
-9 stimulation by producing IFN-b mRNA (Figure 1C)
and protein (Figure 1B), but did respond normally to stim-
ulation with poly(I:C). Similar results were obtained for
IFN-a (Figure 1A) and IFN-l (data not shown) levels de-
termined by ELISA, with normal induction by poly(I:C)
and a lack of induction by TLR-7, -8, and -9 agonists, in-
cluding GU-rich ssRNA (data not shown). The TLR-4-
mediated induction of IFN-b mRNA in response to LPS
was detected in the patients (Figure 1C). The mean
levels of IFN-a/b and IFN-l mRNA or protein produced
in response to poly(I:C) and LPS in patients and controls
were not statistically different (t test, p values > 0.05).
Moreover, IFN-a production was normal in IRAK-4-
deficient blood cells from P7 costimulated with IFN-b
to increase TLR-3 expression (Siren et al., 2005) and
with poly(I:C) (Figure 1D). As in two other patients tested
(P1 and P7; data not shown), IFN-a/b and IFN-l re-
sponses to TLR-3 and -4 agonists were normal in four
IRAK-4-deficient patients, but no induction of IL-6 was
observed on ELISA (Picard et al., 2003; data not shown).
Monocyte subsets, plasmacytoid dendritic cells (PDCs),
and myeloid dendritic cells (MDCs) were present in
normal numbers in the peripheral blood of two IRAK-4-
deficient patients (P2 and P3) (Figure 2; Supplemental
Data). The lack of induction of IFN-a/b and IFN-l upon
TLR-7-9 stimulation in IRAK-4-deficient patients there-
fore did not result from the lack of PDCs (Coccia et al.,
2004; Kadowaki et al., 2001). Moreover, the normal induc-
tion of IFN-a/b and IFN-l upon stimulation by viruses and
poly(I:C) indicated that the lack of induction of IFN-a/b
and IFN-l upon TLR-7-9 stimulation in IRAK-4-deficientpatients was due to impaired TLR signaling rather than
deficiencies in the IFN-a/b and IFN-l machinery.
Investigation of IFN-a/b- and -l-Inducible Genes
in IRAK-4-Deficient Blood Cells
IFN-a/b and IFN-l induce the expression of numerous
genes exerting early, innate antiviral immunity—as is
the case for the myxovirus-resistance protein gene
(MX1), also induced by IFN-l (Kotenko et al., 2003)—or
late, adaptive antiviral immunity—as for the genes en-
coding CD40, CD80, and CD86 (Akira and Takeda,
2004; Beutler, 2004; Hoebe et al., 2003b; Pestka et al.,
2004). We first investigated the expression of CD40,
CD80, and CD86 on the surface of blood monocytes
and B cells from healthy controls and four IRAK-4-
deficient patients (P2, P3, P4, and P7) after 24 hr of stim-
ulation of monocytes and PBMCs with agonists of TLR-
3, -4, -7/8 (stimulating monocytes), and -9 (B cells) (Sup-
plemental Data). TLR-7/8 and -9 agonists did not induce
the upregulation of CD40, CD80, and CD86 in mono-
cytes and B cells, respectively, from the four patients,
in contrast to what was observed in control cells (Figure
3A and data not shown). Conversely, TLR-3 and TLR-4
agonists induced upregulation of the three costimula-
tory molecules to similar extents in patients and con-
trols. LPS was the least potent stimulus, consistent
with its relatively weak induction of IFN-a/b (Figure 1).
With all stimuli, including poly(I:C), CD86 was less
strongly induced than CD40 and CD80. We then investi-
gated the MX1 gene, which was normally induced by
HSV-1, VSV, and TLR-3 and -4 agonists in PBMCs
from the two patients tested (P3 and P4) (Figure 3B;
Supplemental Data). In contrast, TLR-7, -8, and -9 ago-
nists did not induce MX1 mRNA in the IRAK-4-deficient
patients studied. Thus, the TLR-7-, -8-, and -9-mediated
IRAK-4 Deficiency and IFN Production
469Figure 3. Induction of the CD40, CD80, and CD86 Costimulatory Molecules andMX1mRNA in Response to TLR-3, -4, -7, -8, and -9 Stimulation in
IRAK-4-Deficient Patients
(A) Monocytes and PBMCs isolated from a control and from patient P3 were untreated or stimulated with poly(I:C) (50 mg/ml, TLR-3), LPS (1 mg/
ml, TLR-4), R-848 (5 mg/ml, TLR-7/8), or CpG-C274 (5 mg/ml, TLR-9) for 24 hr. The expression of CD40, CD80, and CD86 was analyzed by flow
cytometry in poly(I:C)-, LPS-, or R-848-stimulated (shaded bar) or unstimulated (white bar) CD14+ monocytes and in CpG-C274-stimulated
(shaded bar) or unstimulated (white bar) CD19+ B lymphocytes. This experiment is representative of two independent experiments and was
also performed on three other patients, once each.
(B) PBMCs isolated from two controls and from patients P3 and P4 were left unstimulated or were stimulated with TLR agonists for 6 hr (in the
conditions described in [A]) or infected with HSV-1 and VSV for 24 hr (see Supplemental Data for the multiplicities of infection, moi). Total RNA
was extracted and analyzed by reverse transcription and real-time quantitative PCR to determine MX1 mRNA levels. Means and standard de-
viations (SD) were calculated from two experiments.pathway of IFN-a/b and IFN-l induction was completely
abolished in blood cells from IRAK-4-deficient patients,
as shown by direct IFN-a/b and IFN-l determination or
analysis of the level of expression of IFN-a/b- and IFN-
l-inducible genes. In contrast, the TLR-3/4-IFN-a/b/l
pathway was apparently intact.
Viral Induction of IFN-a/b and IFN-l in IRAK-4-
Deficient Blood Cells
We assessed the induction of IFN-a/b and IFN-l by 11
viruses, including ss(-)RNA (VSV, NDV, measles virus,Sendai virus, mumps virus, parainfluenza virus-III),
ss(+)RNA (Sindbis virus, EMCV, coxsakievirus B1
[CVB1]), and dsDNA (HSV-1, BK) viruses (Supplemental
Data). The induction of IFN-a/b by nine viruses in three
patients (P2, P3, and P7) was clearly detectable, similar
to (HSV-1, BK, Sendai, EMCV; t test, p values > 0.05) or
weaker than (VSV, measles, Para III, NDV, Sindbis; t test,
p values < 0.05) that in 14 healthy controls, as shown by
Q-PCR for IFN-b (Figure 4A) and by ELISA for IFN-b (data
not shown) and IFN-a (Figure 4B). The pattern of induc-
tion of IFN-l by these nine viruses in one patient (P7) was
Immunity
470Figure 4. Production of IFN-a/b, IFN-l, and
TNF-a after Stimulation with Viruses in IRAK-
4-Deficient Blood Cells
PBMCs from controls and/or from IRAK-4-
deficient patients P2, P3, or P7 were left un-
stimulated or stimulated with various intact
and UV-inactivated viruses.
(A) IFN-b mRNA levels were analyzed by re-
verse transcription and real-time quantitative
PCR 24 hr after stimulation with intact viruses
(see Supplemental Data for the multiplicities
of infection, moi). Means and standard devia-
tions (SD) were calculated for the controls from
three independent individuals, each tested
once. The patients were each tested once.
(B and C) IFN-a secretion (B) and IFN-l secre-
tion (C) were measured by ELISA after 24 hr of
stimulation. Means and standard deviations
(SD) were calculated for the controls from 14
independent individuals, each tested once.
(D) IFN-a secretion by control PBMCs was
measured by ELISA after 24 hr of stimulation
by intact or UV-inactivated viruses. Means
and standard deviations (SD) were calculated
for the controls from seven independent indi-
viduals, each tested once.
(E) TNF-a secretion was measured by ELISA
after 24 hr of stimulation by two intact vi-
ruses. Means and standard deviations (SD)
for controls were calculated from two inde-
pendent individuals.similar, with the possible exceptions of NDV (high in-
ducer) and Sindbis virus (low inducer) (Figure 4C and
data not shown). Control blood cell stimulation with
UV-inactivated aliquots of the nine viruses resulted in
the normal induction of IFN-a (Figure 4D), IFN-b (data
not shown), and IFN-l (data not shown), suggesting
that the parental viral strains did not require replication
to induce IFNs. Similar results were obtained in three pa-
tients (P2, P5, and P7). We did not determine whether
these nine viruses actually infected and replicated within
blood cells. In contrast, P2, P3, and P7 showed little or
no induction of IFN-a/b and IFN-l in response to the re-
maining two viruses tested, mumps virus and CVB1 vi-rus (Figures 4A–4C). The production of IL-6 and TNF-a
in response to these two viruses was normal (mumps)
or subnormal (CVB1) in the two patients tested (P2 and
P3) (Figure 4E and data not shown). Moreover, the stim-
ulation of control blood cells with UV-inactivated CVB1
virus gave impaired induction of IFN-a (Figure 4D),
IFN-b (data not shown), and IFN-l (data not shown),
whereas this was not the case for the mumps virus, sug-
gesting that infection was required for IFN production
for at least one of the two IRAK-4-dependent viruses.
However, neither of the viruses seemed to replicate in
control and IRAK-4-deficient blood cells, as shown by
a decrease in supernatant viral titers in 48 hr (data not
IRAK-4 Deficiency and IFN Production
471Figure 5. IFN-b, IFN-l, and IL-6 Induction in IRAK-4-Deficient Fibroblasts upon Stimulation by Poly(I:C), IL-1b, TNF-a, and Viruses
Induction of IFN-b, IFN-l, and IL-6 in response to poly(I:C) (50 mg/ml), IL-1b (20 ng/ml), TNF-a (10 ng/ml), and viral stimulations in IRAK-4-deficient
(P1, P2, or P4) and control fibroblasts.
(A and B) IFN-b mRNA induction, as determined by Q-PCR 2 hr after stimulation (A) and IFN-b, as determined by ELISA 24 hr after stimulation (B).
Means and standard deviations (SD) were calculated for each patient from two experiments, and for the controls from two independent individ-
uals, each tested twice.
(C) IFN-b and IFN-l as determined by ELISA 24 hr after stimulation by poly(I:C), following prior treatment with IFN-a2b (105U/ml for 12 hr). This
experiment is representative of two independent experiments.
(D) IL-6, as determined by ELISA 24 hr after stimulation. Means and standard deviations (SD) were calculated for each patient from two experi-
ments, and for the controls from two independent individuals, each tested twice.
(E) IFN-b mRNA induction 24 hr after stimulation by seven intact viruses (see Supplemental Data for the multiplicities of infection, moi). Means
and standard deviations (SD) were calculated for each patient from two experiments, and for the controls from two independent individuals, each
tested twice.shown). IRAK-4 may therefore be required for the induc-
tion of IFNs by CVB1 and mumps virus via its involve-
ment in the viral cycle (Avota et al., 2001), or via its role
as a critical component of the cellular IFN pathway, or
both. The induction of IFN-a/b and IFN-l by 9 of the 11
viruses tested in blood cells was nevertheless detect-
able, suggesting that TLR-7-9 are partly redundant in
sensing these viruses in blood cells in vitro.
IFN-b and IFN-l Induction by Poly(I:C) and Viruses
in IRAK-4-Deficient Fibroblasts
We studied SV-40-transformed fibroblast cell lines from
three of our patients (P1, P2, and P4) and from two
healthy controls. Human fibroblasts express a single
TLR, TLR-3, respond to only one known TLR agonist,
poly(I:C), and secrete IFN-b and IFN-l (this report). IL-6,IL-8, IFN-b, and IFN-l were determined by ELISA in the
supernatant of fibroblasts stimulated with poly(I:C), IL-
1b, and TNF-a. We found that IL-1b and TNF-a induced
the production of IFN-b mRNA (Figure 5A) and protein
(Figure 5B) and of IFN-l (data not shown) in healthy fi-
broblasts. IFN-b was induced by poly(I:C) and TNF-a
but not by IL-1b in IRAK4-deficient fibroblasts (Figures
5A and 5B). The IFN-b and IFN-l response of IRAK-4-
deficient fibroblasts from P2 stimulated with IFN-a to in-
crease TLR-3 expression (Siren et al., 2005) was almost
normal (Figure 5C). We also found that IL-6 was secreted
in IRAK-4-deficient fibroblasts in response to poly(I:C)
(Figure 5D), in contrast to what was observed with blood
cells (Picard et al., 2003; data not shown). We then stud-
ied the impact of IRAK-4 deficiency on virus-induced
IFN-b and IFN-l production by fibroblasts from patients
Immunity
472P1, P2, and P4. Only 7 of the 11 viruses tested induced
IFN-b in two control fibroblastic cell lines (HSV-1, BK,
VSV, measles, Para-III, Sindbis, EMCV); these viruses
also induced IFN-l (Figure 5E and data not shown).
The stimulation of IRAK-4-deficient fibroblasts with all
the viruses that activated control fibroblasts, including
HSV-1 and VSV, led to normal IFN-b (data not shown) in-
duction in the patients tested (Figure 5E). No IFN-b in-
duction was found with five of seven UV-inactivated vi-
ruses in both controls and patients (not BK virus or
HSV-1, data not shown). The induction of IFN-l in the pa-
tients by the intact viruses was normal (data not shown).
Thus, TNF-a-, poly(I:C)-, and virus-induced, but not IL-
1b-induced, IFN-b and IFN-l production occurred nor-
mally in IRAK-4-deficient fibroblasts.
IFN-b- and IL-6-Inducing Pathways in IRAK-4-
Deficient Fibroblasts Stimulated with Poly(I:C)
and Viruses
IFN-b can be induced by poly(I:C) via IRF-3, NF-kB, and
AP-1 (Taniguchi and Takaoka, 2002). The poly(I:C)-re-
sponsive TLR-3 signaling pathway in human cells has
been shown to be IRAK-1 independent (Jiang et al.,
2003). We first assessed the activation of NF-kB in
IRAK-4-deficient fibroblasts stimulated with poly(I:C),
IL-1b, and TNF-a. We observed normal DNA binding ac-
tivity of NF-kB dimers (consisting of p50 and p65, data
not shown) in response to poly(I:C) and TNF-a, in con-
trast to the impaired response to IL-1b observed in cell
lines from patients (Figure 6A). We then investigated
IRF-3 dimerization in response to poly(I:C) and found
that IRF-3 dimers formed normally in the patients’ fibro-
blast cell lines (Figure 6B). Finally, we tested the activa-
tion of p38 and JNK MAP-kinases (MAPK) by Western
blotting to assess the phosphorylation of these kinases.
MAPK were activated equally strongly in response to
poly(I:C) and TNF-a, in the patients’ and control cell
lines, but not in response to IL-1b (Figure 6C). Our find-
ings thus indicate that the activation of IRF-3, NF-kB,
and MAPK is IRAK-4 independent in human fibroblasts
in response to poly(I:C) stimulation. This accounts for
the normal induction of both IFN-b and IL-6 by poly(I:C)
in IRAK-4-deficient fibroblasts (Figures 5B and 5D). We
then assessed the activation of NF-kB and IRF-3 in
response to stimulation with HSV-1 and VSV. IRAK-4-
deficient fibroblasts showed normal activation of NF-kB
(Figure 6D) and IRF-3 (Figure 6E). Thus, the pathways
leading to IFN-b production in response to HSV-1 and
VSV were intact in IRAK-4-deficient fibroblasts. This
finding accounts at least partly for the normal induction
of IFN-b and IFN-l in IRAK-4-deficient fibroblasts upon
stimulation with the seven viruses capable of inducing
these IFNs in control cells.
TLR-Mediated IFN-Inducing Pathways
in Immortalized and Fresh Blood Cells
We attempted to characterize the signaling pathways
leading to IFN-a/b and IFN-l secretion in blood cells
from IRAK-4-deficient and control individuals upon
stimulation by TLR agonists and intact viruses. We
used EBV-transformed B cells (EBV-B cells) to study
the signaling pathway downstream from TLR-7/8, as
control EBV-B cells were found to respond to R-848,
3M-2, and 3M-13, but not to any other known TLR ago-nists (data not shown). IRAK-1 was degraded in control
EBV-B cells stimulated with R-848, but not in IRAK-4-
deficient cells, as shown by Western blotting (Figure
7A). TNF-a was not induced by 3M-13, 3M-2, and
R-848 in IRAK-4-deficient EBV-B cells from P2 and P3, in
contrast to control cells, as measured by ELISA (Figure
7B). These results confirm that IRAK-4 is a critical com-
ponent of TLR-7/8 signaling, not only in freshly prepared
blood cells, but also in EBV-B cell lines, in which IRAK-4
is located upstream from IRAK-1 in this signaling path-
way. No IFN-a/b or IFN-l was produced upon stimula-
tion of control EBV-B cells with TLR-7/8 agonists or
HSV-1 (data not shown). We then used fresh peripheral
blood mononuclear cells to investigate the signaling
pathways triggered by poly(I:C), LPS, and R-848. NF-kB
p65 was translocated normally to the nucleus of mono-
cytes from control and IRAK-4-deficient individual P2
in response to poly(I:C) and LPS, but not in response to
R-848 in IRAK-4-deficient monocytes, as shown by im-
munofluorescence (Figure 7C). Nuclei were visualized
by DAPI staining (data not shown) or phase contrast mi-
croscopy (Supplemental Data). Moreover, IRAK-1 was
degraded upon R-848 stimulation in control monocytes,
but not in IRAK-4-deficient monocytes, as shown by
Western blotting with a specific antibody (Figure 7D).
Thus, the signaling pathway leading to IFN-a/b secretion
by blood cells stimulated with poly(I:C) and LPS involves
NF-kB but does not require IRAK-4; conversely, the
pathway leading to IFN-a/b secretion in blood cells stim-
ulated with R-848 involves NF-kB and requires IRAK-4
and IRAK-1.
Discussion
IRAK-4 deficiency in humans abolishes the induction of
IFN-a/b and IFN-l via TLR-7, -8, and -9 in blood cells. We
demonstrated this by measuring IFN-a, IFN-b, and IFN-l
levels and by studying the expression of IFN-a/b-induc-
ible target genes, such as MX1 and the genes encoding
the costimulatory molecules CD40, CD80, and CD86. As
TLR-7 and TLR-8 agonists, we used the imidazoquino-
line compounds R-848, 3M-2, and 3M-13 and GU-rich
ssRNAs 33 and 40 and, as a TLR-9 agonist, the potent
IFN-a/b inducer CpG-C. We also showed that IRAK-4-
deficient monocytes and EBV-B cells did not activate
IRAK-1 in response to TLR-7/8 stimulation. This sug-
gests that IRAK-4 and IRAK-1 are both involved in
TLR-7/9 signaling and that human IRAK-1, downstream
from IRAK-4, may be critical for IRF-7 phosphorylation,
as recently shown in the mouse (Uematsu et al., 2005).
Indeed, a complex formed between MyD88, TRAF-6,
and IRF-7 has been shown to mediate signaling via
TLR-7/8 to induce IFN-a (Honda et al., 2004; Kawai
et al., 2004). Our data thus demonstrate that human
IRAK-4 and, probably, IRAK-1 are critical, nonredundant
components for IFN-a/b induction by blood cells in re-
sponse to TLR-7, TLR-8, and TLR-9. Our study indicates
that the regulation of IFN-l by TLRs follows that of IFN-
a/b, with IRAK-4 being critical for the TLR-7-9-mediated
induction of both IFN-a/b and IFN-l.
In contrast, human IRAK-4 is largely dispensable for
the induction of IFN-a/b and IFN-l in response to TLR-3
and -4 agonists in blood cells, even upon coinduction
of these TLRs by exogenous IFN-b. IRAK-4-deficient
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473Figure 6. IFN-b-Inducing Signaling Pathways in Control and IRAK-4-Deficient Fibroblasts Stimulated with Poly(I:C) and Viruses
SV40-transformed fibroblast lines from a control and from patients P1 and P2 were left unstimulated (labeled ‘‘NS’’) or stimulated with poly(I:C)
(50 mg/ml), IL-1b (20 ng/ml), TNF-a (10 ng/ml), and viruses (see Supplemental Data for the multiplicities of infection).
(A) DNA binding activity of nuclear extracts from fibroblasts left unstimulated or stimulated with poly(I:C) for 2 hr, IL-1b for 20 min, and TNF-a for
40 min was assessed by EMSA, using an NF-kB-specific DNA probe.
(B) IRF-3 dimers and monomers detected by Western blotting in whole-cell extracts from fibroblasts left unstimulated or stimulated with poly(I:C)
for 2 hr.
(C) Phospho-p38, phospho-JNK, and p38 detected by Western blotting in cytoplasmic extracts from fibroblasts left unstimulated or stimulated
with poly(I:C) for 1 hr and IL-1b and TNF-a for 20 min.
(D) DNA binding activity of nuclear extracts from fibroblasts left unstimulated or stimulated with HSV-1 or VSV for 4, 8, and 12 hr was assessed by
EMSA, via an NF-kB-specific DNA probe.
(E) IRF-3 dimers and monomers detected by Western blotting in whole-cell extracts from fibroblasts left unstimulated or stimulated with VSV for
12 hr. These experiments are each representative of two experiments.
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474Figure 7. IFN-a/b-Inducing Signaling Pathways in Control and IRAK-4-Deficient Blood Cells and EBV-B Cells, Stimulated with TLR Agonists
(A) IRAK-1 in EBV-B-cell lines treated with or without R-848 (5 mg/ml) for 2 hr, as determined by Western blotting of whole-cell extracts with an
anti-IRAK-1 antibody and normalized with an anti-STAT-2 antibody.
(B) TNF-a secretion, as measured by ELISA, 24 hr after R-848 (5 mg/ml, TLR7/8), 3M-13 (3 mg/ml, TLR7), and 3M-2 (3 mg/ml, TLR8) stimulation.
Means and standard deviations (SD) were calculated for each patient from two experiments, and for the controls from three independent indi-
viduals, each tested twice.
(C) NF-kB p65 subunit subcellular localization in monocytes from peripheral blood mononuclear cells left unstimulated or stimulated with
poly(I:C) (50 mg/ml), LPS (1 mg/ml), or R-848 (5 mg/ml) for 2 hr, as determined by immunofluorescence analysis.
(D) IRAK-1 in freshly prepared monocytes left unstimulated or stimulated for 2 hr in the same conditions, as detected by Western blotting of
whole-cell extracts, with an anti-IRAK-1 antibody. IRAK-1 and Stat-2 signals were analyzed and quantified using NIH Image version 1.63
(http://rsb.info.nih.gov/nih-image/). IRAK-1 signals were standardized with the corresponding STAT-2 signals, and IRAK-1 degradation was
then evaluated in control and patient monocytes. Standardized IRAK-1 signal in control monocytes is 50% lower than that in patient monocytes
upon R-848 stimulation, whereas IRAK-1 signals were similar in control and patient monocytes after poly(I:C) stimulation.fibroblasts also responded normally to poly(I:C) in terms
of MAPK, NF-kB, and IRF-3 activation, resulting in nor-
mal IFN-b induction, even upon coinduction of TLR-3
by exogenous IFN-a. Thus, the TLR-3-IRF-3/NF-kB/
MAPK-IFN-b and the less well-known TLR-3-IFN-l sig-
naling pathways in fibroblasts do not require IRAK-4 to
be operational. Our study also suggests that IRAK-4 is
redundant for other TLR-3-mediated signals, as the
induction of IL-6 by poly(I:C) was normal in IRAK-4-
deficient fibroblasts. However, blood cells produced
little IL-6 upon stimulation by poly(I:C) (Picard et al.,
2003). A human cell line bearing a somatic mutation in
IRAK-1 was previously shown to respond normally to
TLR-3 stimulation by poly(I:C) (Jiang et al., 2003). In
mice, the TLR-4-mediated induction of IFN-a/b has been
shown to be independent of IRAK-4 (Suzuki et al.,
2003). Our findings show that the induction, in blood
cells, of both IFN-a/b and IFN-l by poly(I:C) is IRAK-4 in-
dependent. The induction of IFN-a/b in response to LPS
was less intense in humans (this report) than in mice
(Suzuki et al., 2003; Toshchakov et al., 2002).
Blood cell subsets expressing these five TLRs were
present in IRAK-4-deficient patients: neutrophils (whichnormally express TLR-4), eosinophils (TLR-7), B cells
(TLR-7 and TLR-9), NK cells (TLR-3 and TLR-9), and
the main producers of IFN-a/b and IFN-l—monocytes
(TLR-4 and TLR-8), MDCs (TLR-3), and PDCs (TLR-7
and -9) (Bekeredjian-Ding et al., 2005; Bourke et al.,
2003; Coccia et al., 2004; Diebold et al., 2003; Kadowaki
et al., 2001; Nagase et al., 2003; Sabroe et al., 2002;
Sivori et al., 2004). The results obtained in healthy indi-
viduals suggest that PDCs (expressing TLR-7 and TLR-9,
triggered by 3M-13 and CpG, respectively) and mono-
cytes (TLR-8, 3M-2) produce similar, large amounts of
IFN-a/b. TLR-3-expressing MDCs were found to pro-
duce IFN-a/b in response to poly(I:C), but in smaller
amounts. We did not test the IFN response of individual
cell subsets to TLR-3/4 and TLR-7/9 stimulation. How-
ever, TLR-7-expressing eosinophils and B cells (Beker-
edjian-Ding et al., 2005; Nagase et al., 2003) produce
little, if any, IFN-a/b, and TLR-4-expressing neutrophils
(Sabroe et al., 2002) were not present in PBMCs. We
did not test other cell types shown to express both
TLR-3 and IFN-a/b, such as mast cells (Kulka et al.,
2004) and epithelial cells (Schaefer et al., 2005), or TLR-4
and IFN-b, such as microglial cells (Jung et al., 2005).
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the TLR-7/9 pathway leading to IFN-a/b and IFN-l pro-
duction by monocytes and PDCs and a redundant com-
ponent of the TLR-3/4-IFN pathway in monocytes and
MDCs.
At least 20 common viruses infect children worldwide,
and most children have been infected with these viruses
by the age of 18 years. These viruses include dsDNA,
ssDNA, ss(+)RNA, ss(2)RNA, and dsRNA viruses (Casa-
nova and Abel, 2004). Several of the 18 known IRAK-4
patients have been infected with some of these viruses,
as shown by serological testing: HSV-1, CMV, EBV, VZV,
HHV-6, parvovirus B19, rubella virus, RSV, and human
metapneumovirus (Supplemental Data). Many patients
have also probably been infected by many other
widespread viruses, such as adenovirus, influenzavirus,
papillomavirus, enterovirus, and coronavirus. As IRAK-
4-deficient patients are naturally resistant to most
human-tropic viruses, in natural infection conditions in
vivo (Casanova and Abel, 2004), our results suggest
that the TLR-7/9 induction of IFN-a/b and IFN-l in hu-
mans is redundant in protective immunity to viruses.
This in turn implies that the TLR-mediated production
of IFN-a/b and IFN-l by human PDCs is redundant. Re-
sistance in vivo correlates with our observation that 9 of
11 viruses tested induced normal or low, but not nil, lev-
els of IFN-a/b and IFN-l in IRAK-4-deficient blood cells
in vitro. The induction of IFN-b and IFN-l by fibroblasts
was also normal, implying that viral induction of IFNs
in human cells may be TLR dependent (Boehme and
Compton, 2004; Finberg and Kurt-Jones, 2004) but
IRAK-4 independent. IRAK-4 appears to be redundant
for protective immunity to most viruses in humans.
However, as only 18 patients with IRAK-4 deficiency
are known, we cannot exclude the possibility of ascer-
tainment bias. Patients with fatal viral infections, involv-
ing mumps virus and coxsackie viruses in particular,
which did not induce IFN-a/b and IFN-l in IRAK-4-defi-
cient blood cells in vitro, may have remained undiag-
nosed (Casanova and Abel, 2004; Ku et al., 2005). Never-
theless, four patients were vaccinated with attenuated
mumps virus with no adverse effect and mounted a spe-
cific antibody response, whereas three others had
tested positive in serological tests for mumps virus.
Moreover, six patients had high titers of serum antibod-
ies against coxsackie viruses. Careful and prolonged
follow-up of the known patients is also warranted. The
observation that imiquimod, an agonist of TLR-7/8, is
active against warts caused by human papillomaviruses
(HPV) suggests that the patients should be carefully fol-
lowed up for HPV-induced mucocutaneous lesions.
More patients with IRAK-4 deficiency, from diverse eth-
nic groups and living in various geographical areas, thus
need to be diagnosed and followed up before we can
draw firm conclusions regarding their exact infectious
phenotype, particularly as concerns viral susceptibility
and resistance. Nevertheless, this study strongly sug-
gests that IRAK-4 deficiency is associated with resis-
tance to most common viruses.
There is currently little evidence that IRAK-4 and TLR-
7/9 play an important role in antiviral immunity, even
in the mouse model of experimental infection. TLR-9-
deficient mice are susceptible to the only virus tested,
MCMV (Krug et al., 2004; Tabeta et al., 2004). In onestudy, IRAK-4-deficient mice showed impaired IFN-g
production in response to lymphocytic choriomeningitis
virus (LCMV), but the outcome of infection was not de-
termined (Suzuki et al., 2002). The human model of nat-
ural infections offers the advantage of defining the eco-
logically relevant functions of immune genes in host
defense (Casanova and Abel, 2004). The TLR-7/9-IRAK-
4-IFN pathway appears to be redundant in protective
immunity against natural infections with common vi-
ruses. Our previous observation of lethal viral diseases
in patients with complete STAT-1 deficiency and im-
paired cellular responses to IFN-a/b (Dupuis et al., 2003)
provides conclusive evidence that human IFN-a/b is cru-
cial for antiviral immunity. The production of protective
levels of IFN-a/b and IFN-l in IRAK-4-deficient and pro-
ficient patients may be dependent on TLR-3 and TLR-4.
Alternatively, this production may be TLR independent,
mediated by other sensors such as PKR (Maggi et al.,
2000), FADD (Balachandran et al., 2004), and RIG-I
(Kato et al., 2005). It is possible that multiple sensors,
including TLRs, operate collectively, certain sensors
being of particular importance for some viruses and not
others. The best approach to resolving this important
question will be to search for novel germline mutations
in human pathways leading to IFN-a/b and IFN-l pro-
duction (Casanova and Abel, 2005).
Experimental Procedures
Viral Stimulations
We stimulated PBMCs from the IRAK-4-deficient patients with vari-
ous intact viruses: ss(2)RNA (vesicular stomatitis virus [VSV, strain
Indiana], Newcastle disease virus [NDV, strain BR24 444], measles
virus [strain Edmonton], Sendai virus [strain E92], mumps virus [vac-
cine strain Urabe], parainfluenzae virus III [Para-III, strain EA102]),
ss(+)RNA (Sindbis virus [strain VR1248 ATCC], encephalomyocardi-
tis virus [EMCV], coxsackievirus B1 [CVB1, strain Conn-5]), and
dsDNA (herpes simplex virus-1 [HSV-1], strain KOS-1; BK, an isolate
from a patient provided by Pierre Lebon, Paris) viruses (Supplemen-
tal Data).
Cytokines, TLR Agonists, and ELISA
PBMCs isolated by Ficoll-Paque density gradient centrifugation or
SV-40-transformed fibroblasts were treated with 10 mg/ml of poly-
myxin B for 30 min (except in the case of LPS stimulation) and stim-
ulated with various agonists of TLRs, IL-1b, and viruses. The super-
natant was recovered after 24 hr of stimulation. ELISA tests for
IFN-a (AbCys SA, Paris, France) and IFN-b (TFB, Fujirebio, Inc., Tokyo,
Japan) were performed according to the kit manufacturer’s instruc-
tions. The IFN-l ELISA was developed in the laboratory. Plates were
coated with 1 mg/ml of anti-human IFN-l mAb (AF1598, R&D Sys-
tems) overnight at 4ºC, and the IFN-l levels in the supernatant
were estimated with a secondary biotinylated anti-human IFN-l
mAb (BAF1598, R&D Systems) used at a concentration of 400 mg/ml
(Supplemental Data).
Antibodies and Flow Cytometry
Peripheral blood mononuclear cells (PBMCs) were stained with anti-
bodies and were analyzed by flow cytometry, using a CyanADP ma-
chine and Summit 4.1 software (DakoCytomation). Monocytes iso-
lated from PBMCs by negative selection (CD3, CD7, CD16, CD19,
CD56, CD123, and glycophorin A) with a monocyte isolation kit (Mil-
tenyi Biotech GmbH) were left unstimulated or were stimulated with
poly(I:C), LPS, and R-848. For B cell studies, PBMCs were left unstim-
ulated or were stimulated with CpG-C (Supplemental Data).
Determination of mRNA Levels by Q-PCR
Total RNA was extracted with Trizol reagent (Invitrogen) from unstim-
ulated PBMCs or from PBMCs stimulated with agonists of TLRs
and viruses. RNA was reverse transcribed directly with Oligo-dT
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mRNA level determination, RNA was treated with RNase-free DNase
(Roche Diagnostics France, Meylan, France) and cleaned by pas-
sage through an RNeasy column (Qiagen S.A. France, Coutaboeuf,
France). It was then subjected to reverse transcription in the pres-
ence of random hexamer primers (Applied Biosystems reverse
transcription kit, Applied Biosystems France, Coutaboeuf, France)
(Supplemental Data).
Signal Transduction Studies
Nuclear extracts were prepared, and electrophoretic mobility shift
assays (EMSA) were performed with an NF-kB-specific DNA probe
as already described (Picard et al., 2003). We used the Bio-Rad pro-
tein assay to ensure that all samples contained similar amounts of
protein. Proteins in the cytoplasmic fraction were Western blotted
and probed with antibodies against phospho-p38 (#9211) and JNK
(#9251) MAP kinase (Cell Signaling Technology, Ozyme, Saint Quen-
tin Yvelines CEDEX, France) and total p38 (C-20, sc-535, Santa Cruz
Biotechnology, Santa Cruz, CA). Proteins in whole-cell extracts were
Western blotted and probed with antibodies against IRF-3 (FL-425,
sc-9082, Santa Cruz), IRAK-1 (H-273, sc-7883, Santa Cruz), and
Stat-2 (A7, sc-1668, Santa Cruz).
Intracellular Staining
Monocytes, unstimulated or stimulated for 1 or 2 hr, with poly(I:C),
LPS, and R-848, were fixed with 3% paraformaldehyde, permeabi-
lized with 0.1% Triton X-100 (Sigma), and incubated with rabbit poly-
clonal antibody against p65 (C-20, sc-372, Santa Cruz) for 30 min,
followed by Alexa Fluor 488 goat anti-rabbit antibody (A-11034; Mo-
lecular Probes, Interchim, Montluc¸on, France) for 30 min. Nuclei
were stained with DAPI or observed by phase contrast microscopy.
The slides were analyzed by confocal microscopy on an LSM 510
confocal microscope.
Supplemental Data
Supplemental Data include one figure and Supplemental Results
and Experimental Procedures and can be found with this article on-
line at http://www.immunity.com/cgi/content/full/23/5/465/DC1/.
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